Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fasting State
NCT07297940Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Dec 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Started Dec 2025; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07297940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297940.